BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 349597)

  • 1. Haloperidol dose, plasma levels, and clinical response: a double-blind study [proceedings].
    Ericksen SE; Hurt SW; Chang S
    Psychopharmacol Bull; 1978 Apr; 14(2):15-6. PubMed ID: 349597
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the therapeutic effects between haloperidol and insulin coma in schizophrenia and optimal blood levels of haloperidol].
    Shu L
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1987 Feb; 20(1):43-8. PubMed ID: 3304870
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
    J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of haloperidol blood level and clinical response: looking through the window.
    Volavka J; Cooper TB
    J Clin Psychopharmacol; 1987 Feb; 7(1):25-30. PubMed ID: 3546403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
    Itoh H
    Psychopharmacol Bull; 1985; 21(1):120-2. PubMed ID: 3885289
    [No Abstract]   [Full Text] [Related]  

  • 8. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
    Fleischhacker WW; Barnas C; Stuppäck CH; Unterweger B; Miller C; Hinterhuber H
    Psychopharmacol Bull; 1989; 25(1):97-100. PubMed ID: 2570438
    [No Abstract]   [Full Text] [Related]  

  • 9. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W; Boisvert D; Bradwejn J
    Psychopharmacol Bull; 1984; 20(1):108-9. PubMed ID: 6371871
    [No Abstract]   [Full Text] [Related]  

  • 10. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AMDP system in international clinical trials: a double-blind comparison of fluperlapine and haloperidol.
    Woggon B; Linden M; Beckmann H; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pflug B; Schied HW
    Psychopharmacol Bull; 1986; 22(1):47-51. PubMed ID: 2873619
    [No Abstract]   [Full Text] [Related]  

  • 12. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC; Kennedy NM; Gribbon D
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic effects of verapamil in schizophrenia.
    Price WA
    Hillside J Clin Psychiatry; 1987; 9(2):225-30. PubMed ID: 3323023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Psychopharmacol Bull; 1988; 24(1):172-5. PubMed ID: 3387519
    [No Abstract]   [Full Text] [Related]  

  • 17. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics.
    Selman FB; McClure RF; Helwig H
    Curr Ther Res Clin Exp; 1976 Jun; 19(6):645-52. PubMed ID: 819222
    [No Abstract]   [Full Text] [Related]  

  • 18. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of haloperidol and clinical response.
    Van Putten T; Marder SR; May PR; Poland RE; O'Brien RP
    Psychopharmacol Bull; 1985; 21(1):69-72. PubMed ID: 3920705
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.